GEN Exclusives

More »

GEN News Highlights

Back to Item »

BARDA to Give Neumedicines $17M to Progress Radiation Countermeasure

Contract is valued at $273 million and is expected to move HemaMax from Phase I to licensure.

Forward this item to a colleague:


(Separate multiple addresses by commas)


(Separate multiple addresses by commas)


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Career Development Woes

What do you consider the greatest threat to your career prospects?

More »